IP Library Granted Patent US 7,060,827
Granted Patent B2
US 7,060,827 · App. 10/858,343 · Granted Jun 13, 2006

Intermediates useful for making 2,4-pyrimidinediamine compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,060,827
App. No.
10/858,343
Granted
Jun 13, 2006
Kind
B2
Abstract

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

Claims (29)

1. A 4-pyrimidineamine compound according to structural formula (II):

including salts, hydrates, solvates and N-oxides thereof, wherein:

X is N;

Y is selected from the group consisting of O, S, SO, SO 2 , SONR 36 , NH, NR 35 and NR 37 ;

Z is selected from the group consisting of O, S, SO, SO 2 , SONR 36 , NH, NR 35 and NR 37 ;

R 5 is selected from the group consisting of R 6 , (C1–C6) alkyl optionally substituted with one or more of the same or different R 8 groups, (C1–C4) alkanyl optionally substituted with one or more of the same or different R 8 groups, (C2–C4) alkenyl optionally substituted with one or more of the same or different R 8 groups and (C2–C4) alkynyl optionally substituted with one or more of the same or different R 8 groups;

R 6 is selected from the group consisting of hydrogen, an electronegative group, —OR d , —SR d , (C1–C3) haloalkyloxy, (C1–C3) perhaloalkyloxy, —NR c R c , halogen, (C1–C3) haloalkyl, (C1–C3) perhaloalkyl, —CF 3 , —CH 2 CF 3 , —CF 2 CF 3 , —CN, —NC, —OCN, —SCN, —NO, —NO 2 , —N 3 , —S(O)R d , —S(O) 2 R d , —S(O) 2 OR d , —S(O)NR c R c ; —S(O) 2 NR c R c , —OS(O)R d , —OS(O) 2 R d , —OS(O) 2 OR d , —OS(O)NR c R c , —OS(O) 2 NR c R c , —C(O)R d , —C(O)OR d , —C(O)NR c R c , —C(NH)NR c R c , —OC(O)R d , —SC(O)R d , —OC(O)OR d , —SC(O)OR d , —OC(O)NR c R c , —SC(O)NR c R c , —OC(NH)NR c R c , —SC(NH)NR c R c , —[NHC(O)] n R d , —[NHC(O)] n OR d , —[NHC(O)] n NR c R c and —[NHC(NH)] n NR c R c , (C5–C10) aryl optionally substituted with one or more of the same or different R 8 groups, phenyl optionally substituted with one or more of the same or different R 8 groups, (C6–C16) arylalkyl optionally substituted with one or more of the same or different R 8 groups, 5–10 membered heteroaryl optionally substituted with one or more of the same or different R 8 groups and 6–16 membered heteroarylalkyl optionally substituted with one or more of the same or different R 8 groups;

R 8 is selected from the group consisting of R a , R b , R a substituted with one or more of the same or different R a or R b , —OR a substituted with one or more of the same or different R a or R b , —B(OR a ) 2 , —B(NR c R c ) 2 , —(CH 2 ) m —R b , —(CHR a ) m —R b , —O—(CH 2 ) m —R b , —S—(CH 2 ) m —R b , —O—CHR a R b , —O—CR a (R b ) 2 , —O—(CHR a ) m —R b , —O—(CH 2 ) m —CH[(CH 2 ) m R b ]R b , —S—(CHR a ) m —R b , —C(O)NH—(CH 2 ) m —R b , —C(O)NH—(CHR a ) m —R b , —O—(CH 2 ) m —C(O)NH—(CH 2 ) m —R b , —S—(CH 2 ) m —C(O)NH—(CH 2 ) m —R b , —O—(CHR a ) m —C(O)NH—(CHR a ) m —R b , —S—(CHR a ) m —C(O)NH—(CHR a ) m —R b , —NH—(CH 2 ) m —R b , —NH—(CHR a ) m —R b , —NH[(CH 2 ) m R b ], —N[(CH 2 ) m R b ] 2 , —NH—C(O)—NH—(CH 2 ) m —R b , —NH—C(O)—(CH 2 ) m —CHR b R b and —NH—(CH 2 ) m —C(O)—NH—(CH 2 ) m —R b ;

each R 35 is, independently of the others, selected from the group consisting of hydrogen and R 8 , or, alternatively, two R 35 bonded to the same carbon atom are taken together to form an oxo (═O), NH or NR 38 group and the other two R 35 are each, independently of one another, selected from the group consisting of hydrogen and R 8 ;

each R 36 is independently selected from the group consisting of hydrogen and (C1–C6) alkyl;

each R 37 is independently selected from the group consisting of hydrogen and a progroup;

R 38 is selected from the group consisting of (C1–C6) alkyl and (C5–C14) aryl;

each R a is independently selected from the group consisting of hydrogen, (C1–C6) alkyl, (C3–C8) cycloalkyl, cyclohexyl, (C4–C11) cycloalkylalkyl, (C5–C10) aryl, phenyl, (C6–C16) arylalkyl, benzyl, 2–6 membered heteroalkyl, 3–8 membered cycloheteroalkyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, 4–11 membered cycloheteroalkylalkyl, 5–10 membered heteroaryl and 6–16 membered heteroarylalkyl;

each R b is a suitable group independently selected from the group consisting of ═O, —OR d , (C1–C3) haloalkyloxy, —OCF 3 , ═S, —SR d , ═NR d , ═NOR d , —NR c R c , halogen, —CF 3 , —CN, —NC, —OCN, —SCN, —NO, —NO 2 , ═N 2 , —N 3 , —S(O)R d , —S(O) 2 R d , —S(O) 2 OR d , —S(O)NR c R c , —S(O) 2 NR c R c , —OS(O)R d , —OS(O) 2 R d , —OS(O) 2 OR d , —OS(O) 2 NR c R c , —C(O)R d , —C(O)OR d , —C(O)NR c R c , —C(NH)NR c R c , —C(NR a )NR c R c , —C(NOH)R a , —C(NOH)NR c R c , —OC(O)R d , —OC(O)OR d , —OC(O)NR c R c , —OC(NH)NR c R c , —OC(NR a )NR c R c , —[NHC(O)] n R d , —[NR a C(O)] n R d , —[NHC(O)] n OR d , —[NR a C(O)] n OR d , —[NHC(O)] n NR c R c , —[NR a C(O)] n NR c R c , —[NHC(NH)] n NR c R c and —[NR a C(NR a )] n NR c R c ;

each R c is independently a protecting group or R a , or, alternatively, each R c is taken together with the nitrogen atom to which it is bonded to form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which may optionally be substituted with one or more of the same or different R a or suitable R b groups;

each R d is independently a protecting group or R a ;

each m is independently an integer from 1 to 3;

each n is independently an integer from 0 to 3; and

LG is a leaving group.

2. The compound of claim 1 in which LG is chloro.

3. The compound of claim 2 in which R 5 is fluoro.

4. The compound of claim 3 in which R 6 is hydrogen.

5. The compound of claim 1 in which Y and Z are each, independently of one another, selected from the group consisting of O and NH.

6. The compound of claim 5 in which Y and Z are each O.

7. The compound of claim 6 in which each R 35 is hydrogen.

8. The compound of claim 5 in which Y is O and Z is NH.

9. The compound of claim 8 in which two R 35 bonded to the same carbon atom are taken together to form an oxo group.

10. The compound of claim 9 in which the other two R 35 are each hydrogen, methyl or fluoro.

11. The compound of claim 1 which is selected from the group consisting of compounds (IIf), (IIg), (IIh), (Iii), (IIj), (IIl), (IIm) and (IIn):

Assignments (4)
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SPELLING OF ASSIGNOR CATHERIE SYLVAIN'S NAME PREVIOUSLY RECORDED ON REEL 022962 FRAME 0651. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT SPELLING IS CATHERINE SYLVAIN. Recorded Sep 27, 2009
From: SINGH, RAJINDER; ARGADE, ANKUSH; PAYAN, DONALD; MOLINEAUX, SUSAN; HOLLAND, SACHA J.; CLOUGH, JEFFREY; KEIM, HOLGER; BHAMIDIPATI, SOMASEKHAR; SYLVAIN, CATHERINE; LI, HUI; ROSSI, ALEXANDER B.
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 023287/0971 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2009
From: SINGH, RAJINDER; ARGADE, ANKUSH; PAYAN, DONALD; MOLINEAUX, SUSAN; HOLLAND, SACHA J.; CLOUGH, JEFFREY; KEIM, HOLGER; BHAMIDIPATI, SOMASEKHAR; SYLVAIN, CATHERIE; LI, HUI; ROSSI, ALEXANDER B.
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 022962/0651 →
CONFIRMATION OF EXCLUSIVE PATENT LICENSE Recorded Aug 15, 2005
From: RIGEL PHARMACEUTICALS, INC.
To: PFIZER INC.
Reel/Frame 016888/0112 →